Klin Farmakol Farm. 2008;22(1):40-44

Systemic Antifungal Drugs

Hanuš Rozsypal1,2
1 Oddělení tropické medicíny, III. klinika infekčních a tropických nemocí 1. LF UK a FN Na Bulovce, Praha
2 III. klinika infekčních a tropických nemocí 1. LF UK a FN Na Bulovce, Praha

Systemic antifungal agents are useful to treat systemic mycoses. Drugs include polyens, antimetabolites, azoles, echinocandins, and others. Main representative of polyens is amphotericin B. To reduce its toxicity, lipid-based formulations were developed. Amphotericin B molecule is bound to lipid vehicle, namely liposome (liposomal amphotericin B), cholesterol disks, with its forms of lipid complex (ABLC), and amphotericin B colloidal dispersion with cholesterol (ABCD). Important group is represented by azoles: older azoles (imidazoles) include ketoconazole and miconazole, newer ones (triazoles) include fluconazole, itraconazole, voriconazole, posaconazole, and ravuconazole. Caspofungin is a representative of new group antifungals, other drugs - micafungin and anidulafungin - are expected. The article mentions single groups, principal representatives and some specific use with suggested dosing schedules. Main indications are documented by results of clinical studies.

Keywords: Key words: systemic antifungal agents, therapy, polyens, azoles, echinocandins, candidosis, aspergillosis, cryptococcosis.

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rozsypal H. Systemic Antifungal Drugs. Klin Farmakol Farm. 2008;22(1):40-44.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Almirante B, Rodríguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2005; 43 (4): 1829-1835. Go to original source... Go to PubMed...
    2. Richet H, Roux P, Des Champs C, et al. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect. 2002; 8 (7): 405-412. Go to original source... Go to PubMed...
    3. Poikonen E, Lyytikäinen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis. 2003; 9 (8): 985-990.
    4. Alangaden GJ, Wahiduzzaman M, Chandrasekar PH and the Bone Marrow Transplant Group. Aspergillosis: The most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis. 2002; 35 (6): 659-664. Go to original source... Go to PubMed...
    5. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis. 2005; 41 (1): 52-59. Go to original source... Go to PubMed...
    6. Haber J, Čermák J, Indrák K, et al. Stanovisko odborných společností k indikaci a použití antimykotik se systémovým účinkem. Klin mikrobiol inf lék 2003; 9 (6): 294-300.
    7. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998; 26 (6): 1383-1396. Go to original source... Go to PubMed...
    8. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002; 35 (4): 359-366. Go to original source... Go to PubMed...
    9. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998; 103 (1): 205-212. Go to original source... Go to PubMed...
    10. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007; 44 (10): 1289-1297. Go to original source... Go to PubMed...
    11. Mayer J, Doubek M, Doubek J, Horký D, Scheer P, Štěpánek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis. 2002; 186 (3): 379-388. Go to original source... Go to PubMed...
    12. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994; 331 (20): 1325-1330. Go to original source... Go to PubMed...
    13. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998; 104 (3): 238-245. Go to original source... Go to PubMed...
    14. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses. 2001; 44 (5): 125-135. Go to original source... Go to PubMed...
    15. Edwards JE Jr, Bodey GP, Bowden RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis.1997; 25 (1): 43-59. Go to original source... Go to PubMed...
    16. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of highdose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003; 36 (10): 1221-1228. Go to original source... Go to PubMed...
    17. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997; 337 (1): 15-21. Go to original source... Go to PubMed...
    18. Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis. 1996; 22 (2): 322-328. Go to original source... Go to PubMed...
    19. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998; 37 (2): 173-180. Go to original source... Go to PubMed...
    20. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347 (6): 408-415. Go to original source... Go to PubMed...
    21. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J Infect. 1993; 26 (2): 133-146. Go to original source... Go to PubMed...
    22. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347 (25): 2020-2029. Go to original source... Go to PubMed...
    23. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007; 369 (9572): 1519-1527. Go to original source... Go to PubMed...
    24. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007; 356 (24): 2472-2482. Go to original source... Go to PubMed...
    25. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004; 36 (5): 372-379. Go to original source... Go to PubMed...
    26. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006; 53 (5): 337-349. Go to original source... Go to PubMed...
    27. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003; 98 (2):292-299. Go to original source... Go to PubMed...
    28. Haber J. Nová antimykotika - jaká jsou a co přinášejí. Remedia 2005; 15 (3): 247-258.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.